Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Collegium Pharmaceutical, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Collegium Pharmaceutical, Inc. - Product Pipeline Review - 2014', provides an overview of the Collegium Pharmaceutical, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Collegium Pharmaceutical, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Collegium Pharmaceutical, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Collegium Pharmaceutical, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Collegium Pharmaceutical, Inc.'s pipeline products Reasons to buy - Evaluate Collegium Pharmaceutical, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Collegium Pharmaceutical, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Collegium Pharmaceutical, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Collegium Pharmaceutical, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Collegium Pharmaceutical, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Collegium Pharmaceutical, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Collegium Pharmaceutical, Inc. Snapshot 5 Collegium Pharmaceutical, Inc. Overview 5 Key Information 5 Key Facts 5 Collegium Pharmaceutical, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Collegium Pharmaceutical, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Collegium Pharmaceutical, Inc. - Pipeline Products Glance 10 Collegium Pharmaceutical, Inc. - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Collegium Pharmaceutical, Inc. - Early Stage Pipeline Products 11 IND/CTA Filed Products/Combination Treatment Modalities 11 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Collegium Pharmaceutical, Inc. - Drug Profiles 14 oxycodone ER 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 oxymorphone 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 COL-171 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 COL-195 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 COL-196 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 milnacipran hydrochloride 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Collegium Pharmaceutical, Inc. - Pipeline Analysis 20 Collegium Pharmaceutical, Inc. - Pipeline Products by Target 20 Collegium Pharmaceutical, Inc. - Pipeline Products by Route of Administration 21 Collegium Pharmaceutical, Inc. - Pipeline Products by Molecule Type 22 Collegium Pharmaceutical, Inc. - Pipeline Products by Mechanism of Action 23 Collegium Pharmaceutical, Inc. - Recent Pipeline Updates 24 Collegium Pharmaceutical, Inc. - Dormant Projects 28 Collegium Pharmaceutical, Inc. - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables Collegium Pharmaceutical, Inc., Key Information 5 Collegium Pharmaceutical, Inc., Key Facts 5 Collegium Pharmaceutical, Inc. - Pipeline by Indication, 2014 7 Collegium Pharmaceutical, Inc. - Pipeline by Stage of Development, 2014 8 Collegium Pharmaceutical, Inc. - Monotherapy Products in Pipeline, 2014 9 Collegium Pharmaceutical, Inc. - Phase III, 2014 10 Collegium Pharmaceutical, Inc. - IND/CTA Filed, 2014 11 Collegium Pharmaceutical, Inc. - Preclinical, 2014 12 Collegium Pharmaceutical, Inc. - Discovery, 2014 13 Collegium Pharmaceutical, Inc. - Pipeline by Target, 2014 20 Collegium Pharmaceutical, Inc. - Pipeline by Route of Administration, 2014 21 Collegium Pharmaceutical, Inc. - Pipeline by Molecule Type, 2014 22 Collegium Pharmaceutical, Inc. - Pipeline Products by Mechanism of Action, 2014 23 Collegium Pharmaceutical, Inc. - Recent Pipeline Updates, 2014 24 Collegium Pharmaceutical, Inc. - Dormant Developmental Projects,2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.